Modulation of Heparin Cofactor II Function by S Protein (Vitronectin) and Formation of a Ternary S Protein-Thrombin-Heparin Cofactor II Complex

Summary

The complement inhibitor S protein, which is identical to the adhesive protein vitronectin, functions as heparin-neutralizing factor by protecting thrombin as well as factor Xa against fast inactivation by antithrombin III. The interference of S protein with glycosaminoglycan-catalyzed inhibition of thrombin by heparin cofactor II was investigated in these studies. S protein significantly counteracted the anticoagulant activity of heparin and pentosan polysulfate but not of dermatan sulfate. In the presence of 0.3 μg/ml heparin, 0.5 μg/ml pentosan polysulfate, or 2 μg/ml dermatan sulfate, S protein induced a concentrationdependent reduction of the inhibition rate of thrombin by heparin cofactor II. This resulted in a decrease of the apparent pseudo first-order rate constants by about 17-fold (heparin), or about 7-fold (pentosan polysulfate), whereas no neutralization of dermatan sulfate was demonstrable at a physiological ratio of S protein to heparin cofactor II. Exposure of the glycosaminoglycan-binding region of S protein by reduction and carboxymethylation of the protein increased the neutralizing activity of S protein towards heparin and pentosan polysulfate. The results of these functional experiments correlated well with the demonstration of direct binding of S protein to both polysaccharides but not to dermatan sulfate. While reduced/carboxymethylated S protein remained also ineffective in neutralizing other dermatan sulfate compounds with varying degree of sulfation, a synthetic highly basic tridecapeptide, representing a portion of the glycosaminoglycan-binding domain of S protein, counteracted their anticoagulant activity. Independent on the polysaccharide used, S protein was found incorporated within a ternary complex with thrombin and heparin cofactor II during the inhibition reaction as judged by crossed immunoelectrophoresis, ultracentrifugation as well as ELISA analysis, emphazising the function of S protein as scavenger protein for enzyme-inhibitor complexes of the coagulation system. These findings demonstrate the role of S protein as effective neutralising plasma protein of the anticoagulant activity of various glycosaminoglycans also with respect to heparin cofactor II. Although the glycosaminoglycan-binding domain of S protein readily neutralized different dermatan sulfate compounds, physiological modulation of heparin cofactor-II-dependent inhibition of thrombin by native S protein appears to be restricted to the vascular compartments, where other glycosaminoglycans than dermatan sulfate appear to be operative.

Key words

Heparin cofactor II - S protein (vitronectin) - Glycosaminogly-can neutralization - Thrombin inhibition - Ternary complex

• References

• 1 Kolb WP, Miiller-Eberhard HJ. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med 1975; 141: 724-735
• 2 Podack ER, Miiller-Eberhard HJ. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9908-9914
• 3 Preissner KT, Wassmuth R, Miiller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 1985; 231: 349-355
• 4 Holmes R. Preparation from human serum of an alpha-one protein which induces the immediate growth of unadapted cells in vitro. J Cell Biol 1967; 32: 297-308
• 5 Jenne D, Stanley KK. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985; 4: 3153-3157
• 6 Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519-2524
• 7 Preissner KT, Heimburger N, Anders E, Miiller-Berghaus G. Physicochemical, immunochemical and functional comparison of human S-protein and vitronectin - Evidence for the identity of both plasma proteins. Biochem Biophys Res Commun 1986; 134: 951-956
• 8 Tomasini J BR, Mosher DE. On the identity of vitronectin and Sprotein: Immunological cross-reactivity and functional studies. Blood 1986; 68: 737-742
• 9 Hayman EG, Pierschbacher MD, Ohgren Y, Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci 1983; 80: 4003-4007
• 10 Barnes DW, Silnutzer J, See C, Shaffer M. Characterization of human serum spreading factor with monoclonal antibody. Proc Natl Acad Sci 1983; 80: 1362-1366
• 11 Barnes DW, Silnutzer J. Isolation of human serum spreading factor. J Biol Chem 1983; 258: 12548-12552
• 12 Fryklund L, Sievertsson H. Primary structure of somatomedin B. A growth hormone-dependent serum factor with protease inhibiting activity. Biochem Biophys Res Commun 1978; 87: 55-60
• 13 Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: A versatile cell recognition signal. Cell 1986; 44: 517-518
• 14 Preissner KT, Miiller-Berghaus G. S-protein modulates the heparincatalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S-protein with heparin. Eur J Biochem 1986; 156: 645-650
• 15 Preissner KT, Miiller-Berghaus G. Neutralisation and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 1987; 262: 12247-12253
• 16 Heimburger N, Haupt H, Kranz T, Baudner S. Humanserumproteine mit hoher Affinitat zu Carboxymethylcellulose, II. Physikalischchemische und immunologische Charakterisierung eines histidinreichen 3,8 S-2-alpha-Glykoproteins (CM-Protein I). Hoppe-Seylers Z Physiol Chem 1972; 353: 1133-1140
• 17 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-3808
• 18 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976; 251: 4273-4282
• 19 Jordan RE, Favreau LV, Braswell EH, Rosenberg RD. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem 1982; 257: 400-406
• 20 Lane DA, Flynn AM, Pejler G, Lindahl U, Choay J, Preissner K. Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J Biol Chem 1987; 262: 16343-16348
• 21 Podack ER, Curd JG, Griffith JH, Miiller-Eberhard HJ. Dual function of the S-protein in the complement and coagulation system of human plasma. Clin Res 1978; 26: 507
• 22 Jenne D, Hugo F, Bhakdi S. Interaction of complement S-protein with thrombin-antithrombin complexes: A role for the S-protein in haemostasis. Prog Hemostas Thromb 1985; 38: 401-412
• 23 III C R, Ruoslahti E. Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 1985; 260: 15610-15615
• 24 Podack ER, Dahlback B, Griffin JH. Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. J Biol Chem 1986; 261: 7387-7392
• 25 Preissner KT, Zwicker L, Miiller-Berghaus G. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J 1987; 243: 105-111
• 26 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X. Thromb Res 1974; 4: 463-467
• 27 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 28 Wunderwald P, Schrenk WJ, Port H. Antithrombin BM from human plasma: An antithrombin binding moderately to heparin. Thromb Res 1982; 25: 177-191
• 29 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 30 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501-3505
• 31 Siù P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemostas 1985; 54: 635-638
• 32 Fenton II JW, Fasco MJ. Polyethylene glycol 6,000 enhancement of the clotting of fibrinogen solutions in visual and mechanical assays. Thromb Res 1974; 4: 809-817
• 33 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 34 Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide, l,3,4,6-tetrachloro-3a,6a-diphenyl-gly-coluril. Biochem Biophys Res Commun 1978; 80: 849-857
• 35 Ganrot PO. Crossed Immunoelectrophoresis. Scand J Clin Lab Invest 1972; 29: 39-47
• 36 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 37 Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986
• 38 Danielsson A, Raub E, Lindahl U, Björk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-15473
• 39 Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-867
• 40 Sie P, Lansen J, Lacheretz F, Verschuere B, Boneu B. Comparative turn-over of heparin cofactor II and antithrombin III in baboons. Thromb Haemostas 1986; 56: 302-307
• 41 Tollefsen DM, Peacock ME, Monafo WJ. Molecular Size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. J Biol Chem 1986; 261: 8854-8858
• 42 Scully MF, Ellis V, Kakkar VV. Pentosan polysulphate: Activation of heparin cofactor II or antithrombin III according to molecular weight fractionation. Thromb Res 1986; 41: 489-499
• 43 Tollefsen DM, Pestka CA. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. J Clin Invest 1985; 75: 496-501
• 44 Koide T, Foster D, Odani S. The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III FEBS Lett 1986; 194: 242-244
• 45 Hortin G, Tollefsen DM, Strauss AW. Identification of two sites of sulfation of human heparin cofactor II. J Biol Chem 1986; 261: 15827-15830
• 46 Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli . Biochemistry 1988; 27: 752-759
• 47 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
• 48 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; 01: 413-414
• 49 Sie P, Dupony D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; 01: 414-415
• 50 Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJ P. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200
• 51 Lennarz WJ. (ed.). The Biochemistry of Glycoproteins and Proteoglycans. Plenum Press; New York: 1980